
## Mohamed Naguib

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4989580/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sugammadex: Another Milestone in Clinical Neuromuscular Pharmacology. Anesthesia and Analgesia, 2007, 104, 575-581.	2.2	291
2	A Survey of Current Management of Neuromuscular Block in the United States and Europe. Anesthesia and Analgesia, 2010, 111, 110-119.	2.2	286
3	Consensus Statement on Perioperative Use of Neuromuscular Monitoring. Anesthesia and Analgesia, 2018, 127, 71-80.	2.2	207
4	Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiology of Aging, 2013, 34, 791-804.	3.1	139
5	Advances in Neurobiology of the Neuromuscular Junction. Anesthesiology, 2002, 96, 202-231.	2.5	131
6	Optimal Dose of Succinylcholine Revisited. Anesthesiology, 2003, 99, 1045-1049.	2.5	120
7	Predictive Performance of Three Multivariate Difficult Tracheal Intubation Models: A Double-Blind, Case-Controlled Study. Anesthesia and Analgesia, 2006, 102, 818-824.	2.2	114
8	An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Current Opinion in Anaesthesiology, 2018, 31, 407-414.	2.0	94
9	Melatonin and anesthesia: a clinical perspective. Journal of Pineal Research, 2007, 42, 12-21.	7.4	82
10	Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nature Neuroscience, 2014, 17, 223-231.	14.8	82
11	6-Methoxy- <i>N</i> -alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. Journal of Medicinal Chemistry, 2009, 52, 433-444.	6.4	74
12	2,3â€Dihydroâ€1â€Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptorâ€2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligandâ€Steered Modeling. ChemMedChem, 2009, 4, 1615-1629.	3.2	71
13	The Dose of Succinylcholine Required for Excellent Endotracheal Intubating Conditions. Anesthesia and Analgesia, 2006, 102, 151-155.	2.2	64
14	Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System. Anesthesia and Analgesia, 2012, 114, 1104-1120.	2.2	63
15	Epigenetic Manipulation of Brain-derived Neurotrophic Factor Improves Memory Deficiency Induced by Neonatal Anesthesia in Rats. Anesthesiology, 2016, 124, 624-640.	2.5	60
16	Design and Synthesis of a Novel Series of <i>N</i> -Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry, 2008, 51, 4932-4947.	6.4	59
17	Anesthesiologists' Overconfidence in Their Perceived Knowledge of Neuromuscular Monitoring and Its Relevance to All Aspects of Medical Practice: An International Survey. Anesthesia and Analgesia, 2019, 128, 1118-1126.	2.2	55
18	Activation of mGluR1 Mediates C1q-Dependent Microglial Phagocytosis of Glutamatergic Synapses in Alzheimer's Rodent Models. Molecular Neurobiology, 2019, 56, 5568-5585.	4.0	53

Mohamed Naguib

#	Article	IF	CITATIONS
19	Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiology of Aging, 2013, 34, 2843-2852.	3.1	52
20	The Myth of Rescue Reversal in "Can't Intubate, Can't Ventilate―Scenarios. Anesthesia and Analgesia 2016, 123, 82-92.	<sup>1</sup> , 2.2	52
21	Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease. European Journal of Pharmacology, 2017, 811, 12-20.	3.5	51
22	Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. Journal of Pain, 2019, 20, 501-514.	1.4	49
23	Is deep neuromuscular block beneficial in laparoscopic surgery? No, probably not. Acta Anaesthesiologica Scandinavica, 2016, 60, 717-722.	1.6	48
24	Increased synaptic GluR1 subunits in the anterior cingulate cortex of rats with peripheral inflammation. European Journal of Pharmacology, 2011, 653, 26-31.	3.5	47
25	The Effects of Melatonin Premedication on Propofol and Thiopental Induction Dose–Response Curves: A Prospective, Randomized, Double-Blind Study. Anesthesia and Analgesia, 2006, 103, 1448-1452.	2.2	43
26	Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain. Anesthesia and Analgesia, 2010, 111, 99-109.	2.2	41
27	Residual Neuromuscular Block: Rediscovering the Obvious. Anesthesia and Analgesia, 2008, 107, 11-14.	2.2	37
28	Sugammadex: a novel selective relaxant binding agent. Expert Review of Clinical Pharmacology, 2009, 2, 37-53.	3.1	36
29	Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic postâ€ischemic pain model of complex regional pain syndrome type I in rats. European Journal of Neuroscience, 2016, 44, 3046-3055.	2.6	34
30	Synaptic plasticity and pain aversion. European Journal of Pharmacology, 2011, 667, 26-31.	3.5	26
31	Update on neuromuscular pharmacology. Current Opinion in Anaesthesiology, 2009, 22, 483-490.	2.0	25
32	Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy. Neuroscience, 2014, 260, 185-194.	2.3	25
33	Amyloid Fibril–Induced Astrocytic Glutamate Transporter Disruption Contributes to Complement C1q-Mediated Microglial Pruning of Glutamatergic Synapses. Molecular Neurobiology, 2020, 57, 2290-2300.	4.0	18
34	A synthetic approach for (S)-(3-benzyl-3-methyl-2,3-dihydro-benzofuran-6-yl)-piperidin-1-yl-methanone, a selective CB2 receptor agonist. Tetrahedron Letters, 2012, 53, 3316-3318.	1.4	16
35	Fundamental concepts of epigenetics for consideration in anesthesiology. Current Opinion in Anaesthesiology, 2012, 25, 434-443.	2.0	14
36	Reasoning of an Anomaly. Anesthesia and Analgesia, 2013, 117, 297-300.	2.2	13

Mohamed Naguib

#	Article	IF	CITATIONS
37	In Vivo Efficacy of Enabling Formulations Based on Hydroxypropyl-β-Cyclodextrins, Micellar Preparation, and Liposomes for the Lipophilic Cannabinoid CB2 Agonist, MDA7. Journal of Pharmaceutical Sciences, 2013, 102, 352-364.	3.3	12
38	Amyloid fibrils induce dysfunction of hippocampal glutamatergic silent synapses. Hippocampus, 2018, 28, 549-556.	1.9	11
39	Innovative Disruption in the World of Neuromuscular Blockade. Anesthesiology, 2017, 126, 12-15.	2.5	10
40	Suppression of hippocampal GABAergic transmission impairs memory in rodent models of Alzheimer's disease. European Journal of Pharmacology, 2022, 917, 174771.	3.5	8
41	Low-dose rocuronium and tracheal intubation. Middle East Journal of Anesthesiology, 2003, 17, 193-204.	0.2	8
42	How to Catch Unicorns (and Other Fairytales). Anesthesiology, 2018, 128, 1-3.	2.5	7
43	Management Principles to Reduce the Risk of Residual Neuromuscular Blockade. Current Anesthesiology Reports, 2013, 3, 130-138.	2.0	6
44	Neuromuscular Monitoring. Anesthesia and Analgesia, 2019, 128, 1063-1064.	2.2	6
45	Medical Use of Marijuana. Anesthesia and Analgesia, 2015, 121, 1124-1127.	2.2	3
46	Neuromuscular Monitoring as the Art of Probability. Anesthesia and Analgesia, 2017, 124, 1400-1402.	2.2	3
47	Anesthesiology Residents' Documentation of Depth of Neuromuscular Blockade. Anesthesia and Analgesia, 2020, 130, e110-e111.	2.2	3
48	DTâ€02â€05: A NOVEL THERAPEUTIC (NTRXâ€07) TARGETING NEUROINFLAMMATION IN ALZHEIMER'S DISEASE UNDERGOING PHASE I TRIALS. Alzheimer's and Dementia, 2019, 15, P1490.	IS <sub>0.8</sub>	2
49	Neuromuscular monitoring and reversal: responses to the POPULAR study. Lancet Respiratory Medicine,the, 2019, 7, e4.	10.7	2
50	Heuristics, Overconfidence, and Experience With Management of Neuromuscular Block. Anesthesia and Analgesia, 2019, 129, e172-e173.	2.2	2
51	In Reply. Anesthesiology, 2018, 129, 383-384.	2.5	0
52	Management of Neuromuscular Blockade in the Elderly and Morbidly Obese Patient: What Does the Data Show?. Current Anesthesiology Reports, 2020, 10, 107-116.	2.0	0
53	Monitoring Neuromuscular Blockade. , 2013, , 307-327.		Ο